One of the first reports on clinical use of a PI3K/AKT/mTOR inhibitor in ovarian cancer looked at the utility of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways [74]. The gene discussed is AKT1; the disease is ovarian carcinoma.